Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TNYA 
Tenaya Therapeutics Inc (TNYA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: TNYA (3-star) is a STRONG-BUY. BUY since 40 days. Simulated Profits (69.49%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.14
1 Year Target Price $10.14
| 6 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 94.87% | Avg. Invested days 36 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 340.62M USD | Price to earnings Ratio - | 1Y Target Price 10.14 |
Price to earnings Ratio - | 1Y Target Price 10.14 | ||
Volume (30-day avg) 9 | Beta 3.16 | 52 Weeks Range 0.36 - 4.01 | Updated Date 10/14/2025 |
52 Weeks Range 0.36 - 4.01 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -45.12% | Return on Equity (TTM) -85.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 201304763 | Price to Sales(TTM) - |
Enterprise Value 201304763 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.67 | Shares Outstanding 162976102 | Shares Floating 152496739 |
Shares Outstanding 162976102 | Shares Floating 152496739 | ||
Percent Insiders 0.7 | Percent Institutions 22.21 |
Upturn AI SWOT
Tenaya Therapeutics Inc
Company Overview
History and Background
Tenaya Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering therapies that address the underlying causes of heart disease. Founded in 2016, it has evolved into a clinical-stage company with a diverse pipeline of programs.
Core Business Areas
- Gene Therapy: Development of adeno-associated virus (AAV) based gene therapies to correct genetic mutations causing heart failure.
- Precision Medicine: Identification of patient subgroups most likely to respond to their therapies through biomarkers and diagnostics.
- Small Molecule Therapeutics: Developing small molecule therapeutics to modify cellular processes that drive heart failure.
Leadership and Structure
The leadership team includes prominent figures in the biotechnology industry with expertise in cardiology and drug development. The organizational structure is typical of a biotech company, with departments focused on research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- TN-201 (MYK-491): A selective cardiac myosin activator being investigated for the treatment of hypertrophic cardiomyopathy (HCM). Currently in Phase 2 clinical trials. Competitors include Cytokinetics (CYTK).
- Gene Therapy Programs: Several AAV-based gene therapy programs targeting genetic forms of heart failure, including BAG3-associated dilated cardiomyopathy (DCM) and PKP2-associated arrhythmogenic cardiomyopathy (ACM). Competitors include Sarepta Therapeutics (SRPT) in broader genetic therapy space.
Market Dynamics
Industry Overview
The cardiovascular disease therapeutics market is large and growing, driven by aging populations and increasing prevalence of heart failure. Innovation is focused on novel mechanisms of action, including gene therapy and precision medicine approaches.
Positioning
Tenaya Therapeutics is positioned as an innovator in the field of precision cardiology and gene therapy for heart disease. Its competitive advantages include its focus on the underlying genetic causes of heart failure and its diversified pipeline.
Total Addressable Market (TAM)
The global heart failure market is estimated to be worth over $15 billion. Tenaya is positioned to capture a portion of this market with its targeted therapies, depending on clinical trial success and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Strong scientific team
- Innovative gene therapy platform
- Focus on unmet medical needs
- Precision medicine approach
- Diversified pipeline
Weaknesses
- Clinical trial execution risk
- Reliance on external funding
- Limited commercialization experience
- High research and development costs
Opportunities
- Expansion of pipeline to new indications
- Strategic partnerships with larger pharmaceutical companies
- Accelerated regulatory pathways for gene therapies
- Advancements in gene editing technologies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles for gene therapies
- Ethical concerns regarding gene editing
Competitors and Market Share
Key Competitors
- CYTK
- MYOK
- SRPT
Competitive Landscape
Tenaya Therapeutics competes with both large pharmaceutical companies and smaller biotechnology companies in the cardiovascular disease space. Its advantages include its focus on gene therapy and precision medicine, while its disadvantages include its limited commercialization experience and reliance on external funding.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the expansion of its pipeline and advancement of its clinical programs.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of its therapies. Analysts' projections are based on these factors and the potential market size of the targeted indications.
Recent Initiatives: Recent initiatives include advancing TN-201 into Phase 2, progressing gene therapy programs toward clinical trials, and expanding the research pipeline through collaborations and acquisitions.
Summary
Tenaya Therapeutics is a clinical-stage biotechnology company focused on innovative approaches to treating heart disease. Its strengths lie in its gene therapy platform and precision medicine approach. However, it faces clinical trial risks and relies on external funding. Successful clinical trials and regulatory approvals are crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Tenaya Therapeutics Inc. SEC Filings, Company Website, Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on publicly available data and may not be exhaustive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tenaya Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-07-30 | CEO, Interim Principal Financial Officer & Director Mr. Faraz Ali M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 97 | |
Full time employees 97 | |||
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.